Revvity (NYSE:RVTY – Get Free Report) was upgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research note issued on Saturday, Wall Street Zen reports.
A number of other analysts also recently commented on the company. Barclays upped their target price on Revvity from $160.00 to $175.00 and gave the stock an “equal weight” rating in a research note on Wednesday, November 4th. TD Cowen lifted their price target on Revvity from $175.00 to $185.00 and gave the company a “buy” rating in a research report on Wednesday, November 4th. Sanford C. Bernstein reissued a “market perform” rating on shares of Revvity in a report on Thursday. Weiss Ratings raised Revvity from a “hold (c)” rating to a “hold (c+)” rating in a report on Wednesday. Finally, JPMorgan Chase & Co. upped their price objective on Revvity from $155.00 to $160.00 and gave the stock a “neutral” rating in a research report on Wednesday, November 4th. Six investment analysts have rated the stock with a Buy rating and thirteen have issued a Hold rating to the company. Based on data from MarketBeat.com, Revvity has a consensus rating of “Hold” and an average target price of $133.86.
Get Our Latest Report on Revvity
Revvity Price Performance
NYSE:RVTY opened at $154.60 on Friday. Revvity has a one year low of $81.22 and a one year high of $171.74. The company has a debt-to-equity ratio of 0.36, a quick ratio of 2.10 and a current ratio of 2.65. The firm has a market cap of $17.26 billion, a price-to-earnings ratio of 68.41, a PEG ratio of 2.70 and a beta of 1.08. The firm’s fifty day moving average is $150.48 and its two-hundred day moving average is $114.30.
Revvity (NYSE:RVTY – Get Free Report) last released its quarterly earnings data on Tuesday, November 3rd. The company reported $1.38 earnings per share for the quarter, beating analysts’ consensus estimates of $1.30 by $0.08. The business had revenue of $728.90 million during the quarter, compared to analyst estimates of $694.73 million. Revvity had a return on equity of 8.64% and a net margin of 8.61%. The company’s revenue was up 4.3% on a year-over-year basis. During the same quarter last year, the business posted $1.18 EPS. Research analysts expect that Revvity will post 5.42 EPS for the current year.
Insider Activity
In other news, insider Tajinder Vohra sold 7,330 shares of the stock in a transaction dated Wednesday, September 16th. The shares were sold at an average price of $140.88, for a total transaction of $1,032,650.40. Following the sale, the insider directly owned 6,635 shares of the company’s stock, valued at $934,738.80. This represents a 52.49% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Maxwell Krakowiak sold 1,631 shares of the firm’s stock in a transaction dated Monday, September 21st. The shares were sold at an average price of $144.53, for a total value of $235,728.43. Following the sale, the insider owned 14,781 shares in the company, valued at $2,136,297.93. This trade represents a 9.94% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 9,045 shares of company stock worth $1,281,439. Corporate insiders own 0.85% of the company’s stock.
Institutional Trading of Revvity
Several institutional investors have recently bought and sold shares of the business. Pillar Financial Advisors LLC purchased a new stake in shares of Revvity in the third quarter valued at approximately $29,000. Heritage Family Offices LLP purchased a new position in shares of Revvity during the 3rd quarter valued at approximately $37,000. Rothschild Investment LLC purchased a new position in shares of Revvity during the 3rd quarter valued at approximately $43,000. Group One Trading LLC acquired a new stake in Revvity in the 3rd quarter valued at $61,000. Finally, Root Financial Partners LLC acquired a new stake in Revvity in the 3rd quarter valued at $64,000. 86.65% of the stock is owned by institutional investors and hedge funds.
About Revvity
Revvity, Inc. develops and supplies products and services for life sciences research and clinical diagnostics. Its offerings include instruments, reagents, software and related services used by pharmaceutical and biotechnology companies, academic and government research institutions, hospitals and clinical laboratories. The company’s work spans areas such as drug discovery and development, genetic testing, newborn screening and other diagnostic applications. Its technologies help researchers and healthcare providers analyze biological samples and generate information used in research and patient care.
Further Reading
- Five stocks we like better than Revvity
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Revvity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revvity and related companies with MarketBeat.com's FREE daily email newsletter.
